Aether Industries Q3 FY26 Earnings Call Transcript Released
Aether Industries reported a 44% YoY increase in Q3 FY26 consolidated revenue to INR3,171 million and a 75% YoY jump in EBITDA to INR1,083 million. Commercial production from new sites is expected soon. The company is expanding R&D capabilities and focusing on non-pharma/agro sectors. Talent retention is a key priority.
The announcement of strong financial results, progress on new manufacturing sites, expansion into new chemical sectors (electronic chemicals, semiconductor industry), and strategic focus on high-growth segments like CEM and non-pharma/agro will likely have a significant impact on investor perception and the company's future growth trajectory.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT for both the quarter and nine months. Expansion plans are progressing, and new business segments are showing promise, indicating a positive financial and operational outlook.
Aether Industries Limited has released the transcript of their Earning Conference Call held on February 3, 2026. The call discussed the company's financial performance for the third quarter and nine months ended December 31, 2025. Key management personnel, including Dr. Aman Desai, Mr. Rohan Desai, and Mr. Faiz Nagariya, provided insights into the company's business outlook, ongoing expansions, R&D initiatives, and financial highlights.
During the call, it was highlighted that the construction and installation of Site 3++ and the first two production blocks of Site 5 have been completed, with commercial production expected to commence shortly. The company reported robust demand in its large-scale manufacturing vertical, with volume growth exceeding 10% quarter-on-quarter and 25% year-on-year. Three new products targeted towards the pharmaceutical and agrochemical sectors have been added to this vertical, with commercial production planned soon. These products are noted as being manufactured for the first time in India.
Sales from Site 4 increased by 20% quarter-on-quarter to INR60 crores. The company also mentioned progress with its Converge polyol product, expecting to achieve targets for FY2026, and noted increasing customer inquiries. The contract with Otsuka Chemical is on track, targeting INR35-40 crores in sales for FY2026. In the electronic chemicals segment for the semiconductor industry, validation batches have been dispatched to clients in Japan, South Korea, and Taiwan.
Financially, consolidated revenue from operations for Q3 FY26 stood at INR3,171 million, a 44% increase year-on-year. EBITDA rose by 75% to INR1,083 million, with EBITDA margins improving to 34%. Profit After Tax (PAT) increased by 49% to INR645 million, with PAT margins at 20%. For the nine months of FY26, consolidated revenue was INR8,534 million (up 43% year-on-year), EBITDA was INR2,716 million (up 75%), and PAT was INR1,655 million (up 53%).
The company is also undertaking R&D expansions, including installing additional fume hoods and advanced analytical equipment like NMR spectroscopy, to focus more on chemical engineering and scale-up capabilities, particularly for the oil and gas and material sciences sectors. Management emphasized a strong focus on talent retention through attractive ESOPs, packages, and benefits, alongside a culture of leading from the top and empowering employees to stop work for safety issues.
The company is actively pursuing both new customers and increasing wallet share with existing clients in the Contract Engineering Manufacturing (CEM) segment. They highlighted that due to increasing manufacturing costs in Europe, customers are increasingly looking to partner with reliable Indian manufacturers. The company anticipates that by FY27, 70% of its revenue will come from CRAMS and CEM, with 30% from large-scale manufacturing.
What to do with a filing like this
Aether Industries Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aether Industries Limited. Read the original for the full detail.